EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer

Mark Clemons, Carol Stober, Gregory R Pond, Henry Conter, Demetrios Simos, Sukhbinder Dhesy-Thind, Mihaela Mates, Mateya Trinkaus, John Hilton, Marie-France Savard, Dean Fergusson, Lisa Vandermeer und 1 weitere

NEJM Evidence · 26.05.2026 · 5 (6)

DOI: 10.1056/evidoa2500202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 26.05.2026. Verfasst von Mark Clemons und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON. Hauptthemen laut MEDLINE: Breast Neoplasms, Diphosphonates, Imidazoles, Bone Density Conservation Agents. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDiphosphonatesImidazolesBone Density Conservation AgentsHumansZoledronic AcidFemaleMiddle AgedInfusions, IntravenousAgedDrug Administration ScheduleBone NeoplasmsDisease-Free SurvivalChemotherapy, AdjuvantFollow-Up Studies

Substanzen

Zoledronic AcidDiphosphonatesImidazolesBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, ON.
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON.
  • Escarpment Cancer Research Institute and McMaster University, Hamilton, ON, Canada.
  • William Osler Cancer Centre, Brampton, ON, Canada.
  • Stronach Regional Cancer Center, Newmarket, ON, Canada.
  • Department of Oncology, Cancer Centre of Southeastern Ontario and Queen's University, Kingston, ON, Canada.

Zitieren

APA

Clemons, M., Stober, C., Pond, G. R., Conter, H., Simos, D., Dhesy-Thind, S., Mates, M., Trinkaus, M., Hilton, J., Savard, M. F., Fergusson, D., Vandermeer, L., & Awan, A. A. (2026). Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. NEJM Evidence, 5(6). https://doi.org/10.1056/evidoa2500202

Vancouver

Clemons M, Stober C, Pond GR, Conter H, Simos D, Dhesy-Thind S, et al. Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. NEJM Evidence. 2026;5(6). doi:10.1056/evidoa2500202

BibTeX
@article{Clemons2026,
  author = {Clemons, Mark and Stober, Carol and Pond, Gregory R and Conter, Henry and Simos, Demetrios and Dhesy-Thind, Sukhbinder and Mates, Mihaela and Trinkaus, Mateya and Hilton, John and Savard, Marie-France and Fergusson, Dean and Vandermeer, Lisa and Awan, Arif Ali},
  title = {Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer},
  journal = {NEJM Evidence},
  year = {2026},
  volume = {5},
  number = {6},
  doi = {10.1056/evidoa2500202}
}
Kostenlos starten →